CA2055593A1 - Facteur de suppression de l'explosion respiratoire - Google Patents

Facteur de suppression de l'explosion respiratoire

Info

Publication number
CA2055593A1
CA2055593A1 CA002055593A CA2055593A CA2055593A1 CA 2055593 A1 CA2055593 A1 CA 2055593A1 CA 002055593 A CA002055593 A CA 002055593A CA 2055593 A CA2055593 A CA 2055593A CA 2055593 A1 CA2055593 A1 CA 2055593A1
Authority
CA
Canada
Prior art keywords
factor
rbsf
respiratory burst
tgf
inflammatory disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002055593A
Other languages
English (en)
Inventor
Michael A. Narachi
Tsutomu Arakawa
Carl F. Nathan
Subita Srimal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Cornell Research Foundation Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2055593A1 publication Critical patent/CA2055593A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Transplantation (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA002055593A 1990-03-30 1991-03-27 Facteur de suppression de l'explosion respiratoire Abandoned CA2055593A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50231890A 1990-03-30 1990-03-30
US502,318 1990-03-30

Publications (1)

Publication Number Publication Date
CA2055593A1 true CA2055593A1 (fr) 1991-10-01

Family

ID=23997280

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002055593A Abandoned CA2055593A1 (fr) 1990-03-30 1991-03-27 Facteur de suppression de l'explosion respiratoire

Country Status (11)

Country Link
EP (1) EP0477345A1 (fr)
JP (1) JPH04506363A (fr)
KR (1) KR920700677A (fr)
AU (1) AU7699191A (fr)
CA (1) CA2055593A1 (fr)
FI (1) FI915643A0 (fr)
IL (1) IL97725A0 (fr)
NO (1) NO914717L (fr)
NZ (1) NZ237664A (fr)
PT (1) PT97197A (fr)
WO (1) WO1991015223A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3609893A (en) * 1992-01-29 1993-09-01 La Jolla Cancer Research Foundation Methods of controlling the proliferation of macrophages
US5244916A (en) * 1992-01-31 1993-09-14 The Scripps Research Institute Inhibition of respiratory burst using posttranslational modification inhibitors
NZ306832A (en) * 1995-09-19 2001-04-27 Cellular Sciences Inc Compositions for treating mammalian diseases caused by inflammatory response
US20220204553A1 (en) * 2019-05-06 2022-06-30 The University Of Sydney Methods for the fractionation of proteins

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4350764A (en) * 1980-03-10 1982-09-21 The Regents Of The University Of California Microbiological synthesis of beta endorphin
JPS6034997A (ja) * 1983-05-09 1985-02-22 ジヨージ、ジヨセフ、トダロ 生物学的活性ポリペプチド類
US4530838A (en) * 1983-07-08 1985-07-23 The Salk Institute For Biological Studies Synthetic calcitonin-gene-related peptides for lowering blood pressure or gastric acid secretion in mammals
WO1990000900A1 (fr) * 1988-07-20 1990-02-08 Amgen Inc. Procede de traitement de troubles inflammatoires par reduction de l'activation phagocytaire

Also Published As

Publication number Publication date
EP0477345A1 (fr) 1992-04-01
IL97725A0 (en) 1992-06-21
NO914717D0 (no) 1991-11-29
PT97197A (pt) 1991-12-31
NO914717L (no) 1992-01-29
AU7699191A (en) 1991-10-30
WO1991015223A1 (fr) 1991-10-17
NZ237664A (en) 1993-01-27
JPH04506363A (ja) 1992-11-05
FI915643A0 (fi) 1991-11-29
KR920700677A (ko) 1992-08-10

Similar Documents

Publication Publication Date Title
Cavaillon et al. Cytokine response by monocytes and macrophages to free and lipoprotein-bound lipopolysaccharide
AU671073B2 (en) Method and agents for promoting wound healing
Broxmeyer et al. Identification of lactoferrin as the granulocyte-derived inhibitor of colony-stimulating activity production.
EP0451439B1 (fr) Utilisation du "cartilage-inducing factor" (CIF) pour le traitement des troubles hématopoiétiques ou lymphopoiétiques
US4908433A (en) Uses of interleukin-2
DE69133484T2 (de) Verwendung von Staphylococcus-Enterotoxinen oder verwandte Verbindungen für Krebs-Therapie
Baseler et al. Purification of haptoglobin and its effects on lymphocyte and alveolar macrophage responses
Goto et al. Generation of an interleukin-I-like lymphocyte-stimulating factor at inflammatory sites: correlation with the infiltration of polymorphonuclear leucocytes.
US4971952A (en) Method of treating inflammation with cartilage inducing factor
JP2831012B2 (ja) 組換えコロニー刺激因子‐１の使用
NZ211525A (en) Immunosuppressant factor from human glioblastoma cells
DK172578B1 (da) IgE-bindingsfaktorer fra kolostrum fremgangsmåder til fremstilling deraf, anvendelse af disse faktorer samt farmaceutisk pr
CA2055593A1 (fr) Facteur de suppression de l'explosion respiratoire
Tokuyama et al. Purification and identification of TGF-β2-related growth factor from bovine colostrum
FI91484C (fi) Menetelmä uuden solun kasvua säätelevän tekijän, onkostatiini M:n valmistamiseksi
Ichimura et al. Characterization of mouse natural killer cell activating factor (NKAF) induced by OK-432: Evidence for interferon-and interleukin 2-independent NK cell activation
Armstrong et al. Isolation and initial characterization of tumoricidal monokine (s) from the human monocytic leukemia cell line THP-1
Newcom et al. High molecular weight transforming growth factor β is excreted in the urine in active nodular sclerosing Hodgkin's disease
CA2072626A1 (fr) Medicament liberant du cd14
Dopfer et al. In vivo effects of interleukin 2 on lymphocyte subpopulations in a patient with a combined immunodeficiency
JPH0656692A (ja) Ｔｃｆ−ｉｉを有効成分とする創傷治療剤
Tokuyama et al. Purification and identification of TGF-(32-related-growth factor from bovine colostrum
Kin et al. Cellular cooperation in lymphocyte activation. II. Cooperative response of human peripheral T and B lymphocytes to rabbit anti-human beta 2-microglobulin.
WO1993014782A1 (fr) Procedes de regulation de la proliferation des macrophages
US5529982A (en) Inducing granulocyte production or B cell production in peripheral blood by TGF-β

Legal Events

Date Code Title Description
FZDE Discontinued